Stocktoria
AGIOS PHARMACEUTICALS, INC. AGIO
AGIOS PHARMACEUTICALS, INC. (AGIO) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $54.0M at a -764.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.663 |
| Retained earnings / assets | -0.433 |
| EBIT / assets | -0.364 |
| Equity / liabilities | 11.46 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AGIO | AGIOS PHARMACEUTICALS, INC. | 2/9 | 12.52 | — | +48% |
| QTTB | Q32 Bio Inc. | 3/9 | -2.11 | 7.5 | — |
| NKTR | NEKTAR THERAPEUTICS | 1/9 | — | — | -43.9% |
| XOMA | XOMA Royalty Corp | 5/9 | -11.82 | 23.3 | +83.1% |
| OCUL | OCULAR THERAPEUTIX, INC | 3/9 | 3.49 | — | -18.5% |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 3/9 | — | — | +60.2% |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
FAQ
Is AGIO financially healthy?
AGIOS PHARMACEUTICALS, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does AGIO pay a dividend?
No, AGIOS PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is AGIO?
In FY2025, AGIOS PHARMACEUTICALS, INC. had a net margin of -764.0% and a return on equity of -34.6%.
What is the analyst price target for AGIO?
The average Wall-Street price target for AGIOS PHARMACEUTICALS, INC. is $40.75, about 19.1% above the recent price, from 8 analysts (consensus: buy).
Is AGIO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AGIOS PHARMACEUTICALS, INC.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.